ABBVIE INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 164.1 USD | -0.28% |
|
+2.08% | +6.44% |
| May. 17 | Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target | MT |
| May. 17 | ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta... |  |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 55.16B | Sales 2025 * | 58.06B | Capitalization | 291B |
|---|---|---|---|---|---|
| Net income 2024 * | 7.74B | Net income 2025 * | 10.64B | EV / Sales 2024 * | 6.26 x |
| Net Debt 2024 * | 54.72B | Net Debt 2025 * | 47.3B | EV / Sales 2025 * | 5.82 x |
| P/E ratio 2024 * |
32
x | P/E ratio 2025 * |
24.5
x | Employees | 50,000 |
| Yield 2024 * |
3.76% | Yield 2025 * |
3.95% | Free-Float | 96.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie Inc.
More recommendations
More press releases
More news
| 1 day | -0.29% | ||
| 1 week | +2.08% | ||
| Current month | +1.42% | ||
| 1 month | -1.75% | ||
| 3 months | -5.82% | ||
| 6 months | +18.90% | ||
| Current year | +6.44% |
1 week
161.87
166.49
1 month
157.65170.37
Current year
154.77182.89
1 year
130.96182.89
3 years
105.56182.89
5 years
62.55182.89
10 years
45.45182.89
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
| Director/Board Member | 70 | 12-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.12% | 6 M€ | +8.97% | - | |
| 6.85% | 17 M€ | +7.97% | - | |
| 6.26% | 13 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 164.9 | +0.19% | 226 935 |
| 24-05-20 | 164.6 | -1.12% | 3,058,702 |
| 24-05-17 | 166.4 | +1.26% | 5,152,176 |
| 24-05-16 | 164.4 | +0.34% | 4,642,038 |
| 24-05-15 | 163.8 | +1.36% | 5,261,263 |
Delayed Quote Nyse, May 21, 2024 at 09:50 am EDT
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
164.6
USD
Average target price
182.3
USD
Spread / Average Target
+10.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.44% | 291B | |
| +38.67% | 705B | |
| +32.30% | 583B | |
| -2.72% | 364B | |
| +21.15% | 332B | |
| +15.95% | 238B | |
| -3.52% | 210B | |
| +10.56% | 209B | |
| +9.73% | 169B | |
| -0.59% | 162B |
- Stock Market
- Equities
- ABBV Stock
